Plus Therapeutics Secures $15M in Q1, Significantly Reduces Net Loss, Advances Key Programs
PSTV sits 77% above its 52-week low of $2.9.
Summary
Plus Therapeutics reported its first-quarter 2026 financial results, highlighting a significant increase in its cash balance to $15.1 million, primarily due to a $15 million public offering. This cash infusion is critical for a company that previously raised a 'going concern' warning in its last 10-K. The company also reported a substantially reduced net loss of $6.9 million compared to $17.4 million in the prior year's quarter. Operationally, Plus Therapeutics announced new payer coverage for its CNSide diagnostic, expanding covered lives to approximately 81 million, and secured a unique PLA code for billing. For its REYOBIQ program, the company received FDA Orphan Drug Designation for pediatric malignant gliomas and an AMA Category III CPT reimbursement code, alongside progress in manufacturing and FDA discussions. These combined financial and operational advancements provide a strong positive update for the company's stability and product pipeline.
At the time of this announcement, PSTV was trading at $5.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.